Distinction between asymptomatic monoclonal b-cell lymphocytosis with cyclin d1 overexpression and mantle cell lymphoma: From molecular profiling to flow cytometry

Clinical Cancer Research

Volumn 20, Issue 4, 2014, Pages 1007-1019

  Espinet, Blanca ^a,c   Ferrer, Ana ^a,c   Bellosillo, Beatriz ^a,c   Nonell, Lara ^d   Salar, Antonio ^b,c   Fernandez Rodriguez, Concepcion ^c   Puigdecanet, Eulalia ^d   Gimeno, Javier ^a   Garcia Garcia, Mar ^a,c   Carmen Vela, Maria ^a   Luno, Elisa ^k   Collado, Rosa ^l   Navarro, Jose Tomas ^g   De La Banda, Esmeralda ^h   Abrisqueta, Pau ⁱ   Arenillas, Leonor ^a,c   Serrano, Cristina ^m   Lloreta, Josep ^a,c   Minana, Belen ^j   Cerutti, Andrea ^e   Florensa, Lourdes ^a,c   Orfao, Alberto ⁿ   Sanz, Ferran ^f   Sole, Francesc ^a,c   Dominguez Sola, David ^o   Serrano, Sergio ^a,p   more..

^a Servei de Patologia   (United States)

^b Department of Pathology Hospital Del Mar   (United States)

^c Programa de Recerca en C ancer   (United States)

^d Servei d'An alisi de Microarrays   (United States)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^f UNIVERSITAT POMPEU FABRA   (Spain)

^g ICO Hospital Germans Trias i Pujol   (United States)

^h L'Hospitalet de Llobregat   (United States)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j Centre de Regulacio Gen omica   (Spain)

^k HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^m Hospital UniversitarioFundación Jiménez Díaz   (Spain)

ⁿ UNIVERSITY OF SALAMANCA   (Spain)

^o Columbia University ^*  (United States)

^p UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD200 RECEPTOR; CD38 ANTIGEN; CYCLIN D1; TRANSCRIPTION FACTOR SOX11;

ADULT; ARTICLE; ASYMPTOMATIC DISEASE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; INFLAMMATION; MALE; MANTLE CELL LYMPHOMA; MONOCLONAL B CELL LYMPHOCYTOSIS; NEOPLASM; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ASYMPTOMATIC DISEASES; B-LYMPHOCYTES; CASE-CONTROL STUDIES; CYCLIN D1; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; LYMPHOCYTOSIS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSCRIPTOME;

EID: 84896715588     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1077     Document Type: Article

References (57)

1. Swerdlow SH, Campo E, Seto M, Müller-Hermelink HK. Mantle cell lymphoma. In:Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2008. p. 229-32.
2. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999;36:115-27.
3. Hinds PW, Dowdy SF, Eaton EN, Arnold A, Weinberg RA. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A 1994;91:709-13.
4. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA. Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces Bcell lymphoma. Oncogene 2006;25:998-1007.
5. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511-8.
6. Nodit L, Bahler DW, Jacobs SA, Locker J, Swerdlow SH. Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 2003;34:1030-4.
7. Orchard J, Garand R, Davis Z, Babbage G, Sahota S, Matutes E, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003;101:4975-81.
8. Espinet B, Sole F, Pedro C, Garcia M, Bellosillo B, Salido M, et al. Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma? Hum Pathol 2005;36: 1232-7.
9. Fernandez V, Salamero O, Espinet B, Sole F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010;70:1408-18.
10. Ondrejka SL, Lai R, Kumar N, Smith SD, Hsi ED. Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011;96:1121-7.
11. Rule SA, Poplar S, Evans PA, O'Connor SJ,Owen RG. Indolent mantlecell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation. J Clin Oncol 2011;29:e437-9.
12. Del Giudice I, Messina M, Chiaretti S, Santangelo S, Tavolaro S, De Propris MS, et al. Behind the scenes of non-nodal MCL: downmodulation of genes involved in actin cytoskeleton organization, cell projection, cell adhesion, tumour invasion, TP53 pathway and mutated status of immunoglobulin heavy chain genes. Br J Haematol 2012;156: 601-11.
13. Royo C, Navarro A, Clot G, Salaverria I, Gine E, Jares P, et al. Nonnodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012;26:1895-8.
14. Thieblemont C, Nasser V, Felman P, Leroy K, Gazzo S, Callet-Bauchu E, et al. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 2004;103:2727-37.
15. Navarro A, Royo C, Hernandez L, Jares P, Campo E. Molecular pathogenesis of mantle cell lymphoma: new perspectives and challenges with clinical implications. Semin Hematol 2011;48: 155-65.
16. Espinet B, Sole F, Woessner S, Bosch F, Florensa L, Campo E, et al. Translocation (11;14)(q13;q32) and preferential involvement of chromosomes 1, 2, 9, 13, and 17 in mantle cell lymphoma. Cancer Genet Cytogenet 1999;111:92-8.
17. Ventura RA, Martin-Subero JI, Jones M, McParland J, Gesk S, Mason DY, et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J Mol Diagn 2006;8:141-51.
18. van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17: 2257-317.
19. Wiestner A, Tehrani M, Chiorazzi M, Wright G, Gibellini F, Nakayama K, et al. Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood 2007;109:4599-606.
20. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variableregion mutations in chronic lymphocytic leukemia. N Engl J Med 2003;348:1764-75.
21. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4: 249-64.
22. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:Article3.
23. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
24. Bengtsson H, Simpson K, Bullard J, Hansen K. Aroma.affymetrix: a generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory, Tech Report #745, Department of Statistics, University of California, Berkeley, February 2008. [cited 2013 Sep 15]. Available from: http://www.aroma-project.org.
25. Ingenuity Pathway Analysis (Ingenuity Systems). [cited 2013 Sep 15]. Available from: www.ingenuity.com.
26. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50.
27. Gene expression Omnibus, a public functional genomics data repository supporting MIAME-compliant data submissions. [cited 2013 Sep 15]. Available from: http://www.ncbi.nlm.nih.gov/geo.
28. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and Regression Trees. Boca Raton, Florida: Chapman & Hall; 1984.
29. Website for Statistical Computation. The Confidence Interval of a Proportion tool. [cited 2013Sep15].Available from: http://www.vassarstats. net/prop1.html.
30. Pittaluga S, Verhoef G, Criel A, Maes A, Nuyts J, Boogaerts M, et al. Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk Lymphoma 1996;21:115-25.
31. Rawstron AC, Green MJ, Kuzmicki A, Kennedy B, Fenton JA, Evans PA, et al. Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002;100:635-9.
32. Welzel N, Le T, Marculescu R, Mitterbauer G, Chott A, Pott C, et al. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res 2001; 61:1629-36.
33. Salar A, Juanpere N, Bellosillo B, Domingo-Domenech E, Espinet B, Seoane A, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol 2006;30:1274-80.
34. Kuppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999;341:1520-9.
35. Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, fau-Larue MH, Pedersen LB, et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011;118:3088-95.
36. Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A,Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012;72:5307-16.
37. Ek S, Dictor M, Jerkeman M, Jirstrom K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood 2008;111:800-5.
38. Thieblemont C, Houlgatte R, Felman P, Traverse-glehen A, Baseggio L, Rolland D, et al. Indolent Mantle Cell Lymphoma (MCL): a retrospective detailed clinical and morphological analysis of 21 patients, with histological, cytological, cytogenetic, interphase genetic, immunoglobulin gene, and gene expression profiling analysis. ASH Annual Meeting Abstracts 2008;112:1780.
39. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987-94.
40. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008;111:558-65.
41. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209-13.
42. Eve HE, Furtado MV, Hamon MD, Rule SA. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol 2009;27:e189-90.
43. van Zelm MC, Szczepanski T, van der BM, van Dongen JJ. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J Exp Med 2007;204:645-55.
44. Hirt C, Schuler F, Dolken L, Schmidt CA, Dolken G. Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR. Blood 2004;104:904-5.
45. Nieto WG, Almeida J, Romero A, Teodosio C, Lopez A, Henriques AF, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood 2009;114:33-7.
46. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-62.
47. Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 2009;360:659-67.
48. Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T, et al. The DLEU2/ miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010;17:28-40.
49. Nieto WG, Teodosio C, Lopez A, Rodriguez-Caballero A, Romero A, Barcena P, et al. Non-CLL-like monoclonal B-cell lymphocytosis in the general population: prevalence and phenotypic/genetic characteristics. Cytometry B Clin Cytom 2010;78 Suppl 1:S24-34.
50. Vegliante MC, Palomero J, Perez-Galan P, Roue G, Castellano G, Navarro A, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 2013;121:2175-85.
51. Ferrando AA. SOX11 is a mantle cell lymphoma oncogene. Blood 2013;121:2169-70.
52. Nygren L, Baumgartner WS, Klimkowska M, Christensson B, Kimby E, Sander B. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012;119:4215-23.
53. van Dongen JJ, Lhermitte L, Bottcher S, Almeida J, van der Velden VH, Flores-Montero J, et al. EuroFlow antibody panels for standardized ndimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012;26:1908-75.
54. Malavasi F, Deaglio S, Damle R, Cutrona G, Ferrarini M, Chiorazzi N. CD38 and chronic lymphocytic leukemia: a decade later. Blood 2011; 118:3470-8.
55. Zucchetto A, Benedetti D, Tripodo C, Bomben R, Dal Bo M, Marconi D, et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/ vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009;69:4001-9.
56. Dorfman DM, Shahsafaei A. CD200 (OX-2 membrane glycoprotein) expression in b cell-derived neoplasms. Am J Clin Pathol 2010;134: 726-33.
57. Palumbo GA, Parrinello N, Fargione G, Cardillo K, Chiarenza A, Berretta S, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res 2009;33:1212-6.